Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences

Autores
de Kantor, Isabel N.; Barrera, Lucía
Año de publicación
2007
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.
Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results.
Fuente
Medicina (Buenos Aires) 2007; 67(3): 231-237.
Materia
Tuberculosis
Tuberculosis Pulmonar
Mycobacterium tuberculosis
Tuberculosis Resistente a Múltiples Medicamentos
Argentina
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:123456789/144

id SGCANLIS_f8428c312deccf2fdce4df59d43c9830
oai_identifier_str oai:sgc.anlis.gob.ar:123456789/144
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiencesLas pruebas de sensibilidad a drogas de segunda línea y el re-tratamiento de la tuberculosis: visión retrospectiva de tres estudiosde Kantor, Isabel N.Barrera, LucíaTuberculosisTuberculosis PulmonarMycobacterium tuberculosisTuberculosis Resistente a Múltiples MedicamentosArgentinaFil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results.2007info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf0025-7680http://sgc.anlis.gob.ar/handle/123456789/144http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdfMedicina (Buenos Aires) 2007; 67(3): 231-237.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISMedicina (Buenos Aires)ARGenginfo:eu-repo/semantics/openAccess2025-09-04T11:15:12Zoai:sgc.anlis.gob.ar:123456789/144Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:15:12.496Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
Las pruebas de sensibilidad a drogas de segunda línea y el re-tratamiento de la tuberculosis: visión retrospectiva de tres estudios
title Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
spellingShingle Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
de Kantor, Isabel N.
Tuberculosis
Tuberculosis Pulmonar
Mycobacterium tuberculosis
Tuberculosis Resistente a Múltiples Medicamentos
Argentina
title_short Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
title_full Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
title_fullStr Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
title_full_unstemmed Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
title_sort Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences
dc.creator.none.fl_str_mv de Kantor, Isabel N.
Barrera, Lucía
author de Kantor, Isabel N.
author_facet de Kantor, Isabel N.
Barrera, Lucía
author_role author
author2 Barrera, Lucía
author2_role author
dc.subject.none.fl_str_mv Tuberculosis
Tuberculosis Pulmonar
Mycobacterium tuberculosis
Tuberculosis Resistente a Múltiples Medicamentos
Argentina
topic Tuberculosis
Tuberculosis Pulmonar
Mycobacterium tuberculosis
Tuberculosis Resistente a Múltiples Medicamentos
Argentina
dc.description.none.fl_txt_mv Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.
Fil: Barrera, Lucia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
The value of susceptibility tests in guiding antituberculous therapy with second-line drugs remains controversial. We reanalyzed three reports regarding the relationship between in vitro susceptibility of Mycobacterium tuberculosis and the clinical outcome of in-patients treated with these drugs at the Muñiz Hospital, Buenos Aires, during the sixties. These patients had been irregularly treated with a standard regimen consisting of isoniazid, streptomycin and PAS; they developed resistance to at least the first two drugs and persisted culture-positive. Susceptibility testing to ethionamide, cycloserine and kanamycin were performed by the proportion method on Löwenstein Jensen medium. Some level of resistance was detected among isolates from patients not previously treated with these drugs, that could be due to cross resistance with previously administered first line structural analogs. However, the studies evidenced significant association between resistance to ethionamide and cycloserine and prior treatment with these drugs. Increased resistance to all three drugs was detected within the first three months of treatment. In vitro resistance to ethionamide emerged earlier and was the most frequent followed by resistance to cycloserine and kanamycin. The low frequency of resistance to kanamycin could be related to the low dosage of this drug used at that time. Simultaneous resistance to the three agents, but not to two or one drug, appeared to be a marker of treatment failure. An apparent reversion of drug resistance was observed in near 6% of patients, for whom susceptibility tests were repeated on subsequent isolates, indicating this percentage of inconsistency in reproducibility of test results.
description Fil: de Kantor, Isabel N. Organización Mundial de la Salud (OMS). Panel de Consultores en Tuberculosis, Buenos Aires; Argentina.
publishDate 2007
dc.date.none.fl_str_mv 2007
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 0025-7680
http://sgc.anlis.gob.ar/handle/123456789/144
http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdf
identifier_str_mv 0025-7680
url http://sgc.anlis.gob.ar/handle/123456789/144
http://www.medicinabuenosaires.com/revistas/vol67-07/3/completo/v67_3_p231_237.pdf
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Medicina (Buenos Aires)
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.coverage.none.fl_str_mv ARG
dc.source.none.fl_str_mv Medicina (Buenos Aires) 2007; 67(3): 231-237.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1842344417538605056
score 12.623145